Gene Delivery Technologies Market Growth Outlook Through 2024-2033

Overview and Scope
Gene delivery technologies refer to methods that are used to introduce foreign genetic material, such as DNA or RNA, into cells, where the goal of gene delivery is to transfer the genetic material into the target cells. These technologies are commonly used in treating diseases or disorders caused by changed gene-like mutations or an inherited gene.

Sizing and Forecast
The gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.57 billion in 2023 to $4.11 billion in 2024 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to enhanced understanding of genetic diseases, advancements in cell therapy, evolution of nanotechnology, growth of gene therapy trials, research funding increase.

The gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $6.96 billion in 2028 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to precision medicine development, regulatory framework enhancements, proliferation of gene therapy, expansion of non-viral delivery systems. Major trends in the forecast period include application in rare diseases, rise in clinical trials, targeted drug delivery, expansion of cell therapy, development of gene editing tools.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report

Segmentation & Regional Insights
The gene delivery technologies market covered in this report is segmented –

1) By Mode: Biological, Chemical, Physical
2) By Method: Ex Vivo, In Vivo, In Vitro
3) By Application: Gene Therapy, Cell Therapy, Vaccines, Research

North America was the largest region in the gene delivery technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global gene delivery technologies market report during the forecast period. The regions covered in the gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10706&type=smp

Major Driver Impacting Market Growth
The increasing number of cell and gene therapies is expected to propel the growth of the gene delivery technologies market going forward. Cell and gene therapies refer to medical treatments that aim to cure or alleviate diseases by altering a patient’s body’s genetic and cellular makeup. The increasing number of cell and gene therapies is mainly driven by advancements in gene editing technologies, playing a critical role in developing and commercializing cell and gene therapies. For instance, in October 2022, according to an article published by Economist Impact, a UK-based corporation empowering businesses, governments, and foundations to catalyze change and enable progress, in mid-2021 around 2,600 clinical trials for CGTs were underway. Companies have conducted over half of it since 2015, and these have increased as per their research demand in multiple fields. Researchers estimate that by 2031, the United States will have 100 approved CGTs. Additionally, between 2022 and 2031, the FDA is expected to approve 8 or 9 CGTs per year on average. Therefore, increasing cell and gene therapies drives the gene delivery technologies market.

Key Industry Players
Major companies operating in the gene delivery technologies market report are Thermo Fisher Scientific Inc., QIAGEN NV, Horizon Discovery Group Co, OriGene Technologies Inc., Oxford Biomedica Solutions LLC, SignaGen Laboratories LLC, Vectalys SAS, Takara Bio Inc., Bio-Rad Laboratories Inc., System Biosciences LLC, Promega Corporation, Hoffmann-La Roche AG, Catalent Inc., Avantor, Pfizer Inc., Becton Dickinson and Company, Novartis AG, Intellia Therapeutics Inc., Editas Medicine Inc., CRISPR Therapeutics AG, Spark Therapeutics Inc., Bluebird Bio Inc., Sarepta Therapeutics Inc., Regenexxbio Inc., Beam Therapeutics Inc., Verve Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Translate Bio Inc., CureVac N.V., Lonza Group AG

The gene delivery technologies market report table of contents includes:

1. Executive Summary
2. Gene Delivery Technologies Market Characteristics
3. Gene Delivery Technologies Market Trends And Strategies
4. Gene Delivery Technologies Market – Macro Economic Scenario
5. Global Gene Delivery Technologies Market Size and Growth
.
.
.
31. Global Gene Delivery Technologies Market Competitive Benchmarking
32. Global Gene Delivery Technologies Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Gene Delivery Technologies Market
34. Gene Delivery Technologies Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model